Boceprevir is partly metabolized by CYP3A4/5. Quickly memorize the terms, phrases and much more.

Therefore, caution should be used in concomitant administration.

No specific drug-drug interaction study has been performed.The limited data available from a phase IIa study in HIV-infected patients have shown a clinically non significant 20 % decrease of TPV CTipranavir and Viramune can be co-administered without dose adjustments.Due to the metabolic pathway no clinically significant pharmacokinetic interactions are expected between enfuvirtide and nevirapine.Enfuvirtide and Viramune can be co-administered without dose adjustments.Nevirapine concentrations not measured, no effect is expected.Maraviroc and Viramune can be co-administered without dose adjustments.Interaction has not been studied. They are continually being updated and new formulas added. With a number of different sample formulas to choose from, you can benefit from our extensive formula database to help with your day-to-day compounding needs.The Chew-A-Treat sample formulas will help you to produce chewable treats that any animal will love! Cimetidine: no significant effect on cimetidine PK parameters is seen. Cimetidine and Viramune can be co-administered without dose adjustments. No claims are being made as to the safety or clinical efficacy of suggested formulas. No SOPs may be purchased individually.RESPONSES OF THE MEDISCA NETWORK INC. TSS, INCLUDING ALL FORMULAS, WRITTEN ANSWERS TO TECHNICAL QUESTIONS, WRITTEN RESPONSES TO COMPOUNDING INQUIRIES AND FOR CONSULTATION-RELATED QUESTIONS, SOPS AND ANY TOOLS DEVELOPED THROUGH SPECIALIZED CONSULTATION SERVICES ARE AND REMAIN THE PROPERTY OF MEDISCA NETWORK INC. REGISTRANT IS PROVIDED A RESTRICTED LICENSE TO USE IN ITS PRACTICE, AND WILL NOT FURTHER DISSEMINATE OR REDISTRIBUTE FORMULAS, WRITTEN ANSWERS TO TECHNICAL QUESTIONS, WRITTEN RESPONSES TO COMPOUNDING INQUIRIES AND FOR CONSULTATION-RELATED QUESTIONS, SOPS AND ANY TOOLS DEVELOPED THROUGH SPECIALIZED CONSULTATION SERVICES WITHOUT THE EXPRESS WRITTEN CONSENT OF MEDISCA NETWORK INC. By continuing to browse the site you are agreeing to our policy on the use of cookies. The clinical outcome of this observed reduction of boceprevir trough concentrations has not been directly assessed. All suggested SOPs should be validated, approved and authorized for use by the end-user licensed pharmacist prior to use.I hereby agree to the terms and conditions of the MEDISCA Network Inc. Technical Service purchase agreement.

Non-subscribers may view sample content by selecting the appropriate sub-menu. In these patients nevirapine must not be restarted.If patients present with a suspected nevirapine-associated rash, liver function tests should be performed. No clinically relevant drug-drug interaction is expected. MEDISCA Network Inc. and its independent contractor consultants cannot be held liable to any person or entity concerning claims, loss, or damage caused by, or alleged to be caused by, directly or indirectly, the use or misuse of the information contained in suggested formulas, written documentation or verbal consultation. ACCORDINGLY, ANY FORMULAS PROVIDED BY MEDISCA NETWORK INC. ARE UPLOADED TO THE DATABASE AND MADE ACCESSIBLE TO ALL REGISTRANTS, SO THAT THE PHARMACIST COMMUNITY CAN BENEFIT COLLECTIVELY FROM THE RESPECTIVE RESPONSES OF MEDISCA NETWORK INC. TO THE INDIVIDUAL REGISTRANT. Cart - Provider Login. Because the clarithromycin active metabolite has reduced activity against Metabolite 25-O-desacetylrifabutin AUC ↑ 1.24 (0.84-1.84)A clinically not relevant increase in the apparent clearance of nevirapine (by 9 %) compared to historical data was reported.

It is not recommended to co-administer rifampicin and Viramune (see section 4.4).

A compounded product should not be used if the product is available commercially. MEDISCA NETWORK INC. HAS TAKEN SIGNIFICANT MEASURES TO PROTECT ITS PROPERTY, UNDER THE LAW, BY APPLYING TRADEMARKS AND COPYRIGHT TO ITS PRODUCTS AND SERVICES. MEDISCA Network Inc. TSS will issue a user name and password, which are security features of the MEDISCA Network Inc. Website.

Click here to use the documented formula database . Oral hormonal contraceptives should not be used as the sole method of contraception in women taking Viramune (see section 4.4).

Provider Login (0) Compound Ingredients: A-E-I Cream (Scream Cream) … The following formulas are provided for information purposes only and may not be routinely used at Nationwide Children's Hospital.

Interferons (pegylated interferons alfa 2a and alfa 2b) Interferons have no known effect on CYP 3A4 or 2B6. Co-administration of boceprevir with medicines that induce or inhibit CYP3A4/5 could increase or decrease exposure. SOPs may only be purchased as complete sets. Nevirapine levels may increase on stopping St. John's Wort. In this regard, there is an assumption made in pharmaceutical calculations that all measurements in the filling of a prescription or in compounding a formula are performed with equal precision by the pharmacist.

THE DISSEMINATION OR REDISTRIBUTION OF MEDISCA NETWORK INC. TSS PRODUCTS IS STRICTLY PROHIBITED. MEDISCA NETWORK INC. SOPS AND ARE COPYRIGHT © PROTECTED JANUARY 1, 2011. Thus, for example, if the quantities 5.5 grams, 0.01 gram, and 0.005 gram are specified in a formula, they may be added as if they are precise weights, with a sum of 5.515 grams. Formula # 7768. DMPA and Viramune can be co-administered without dose adjustments. The registrant is responsible for the security and confidentiality of this user name and password. By BSA using the Mosteller formula the recommended oral dose for paediatric patients of all ages is 150 mg/m 2 once daily for two weeks followed by 150 mg/m 2 twice daily thereafter. Nevirapine: plasma levels: ↑ 1.15-1.28 compared to historical controls. Therefore, patients who receive nevirapine and zidovudine concomitantly and especially paediatric patients and patients who receive higher zidovudine doses or patients with poor bone marrow reserve, in particular those with advanced HIV disease, have an increased risk of granulocytopenia. Other enzymes may be involved in the metabolism. However, due to the high interpatient variability some patients may experience large increases in rifabutin exposure and may be at higher risk for rifabutin toxicity. The inducing effect may persist for at least 2 weeks after cessation of treatment with St. John's Wort. Interferons and Viramune may be coadministered without dose adjustments.